Table 1.
Characteristics of included studies table
| Author | Year | Country | Study design | Patients | %females | Age | Follow-up months | PSI device | CT/MRI | Eligibility criteria | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PSI | ST | PSI | ST | PSI | ST | ||||||||
| Noble Jr. [7] | 2012 | USA | RCT | 15 | 14 | 47 | 57 | 65.4(57–76) | 68.0(56–80) | NR | Visionaire | MRI | arthritis |
| Pietsch [34] | 2013 | Austria | RCT | 40 | 40 | 68 | 53 | 71.4(6.6) | 69.2(9.4) | 3 months | Materialise | MRI | OA |
| Vundelinckx [35] | 2013 | Belgium | RCT | 31 | 31 | 52 | 65 | 64.7(8.2) | 68.2(8.5) | 6 months | Visionaire | MRI | OA |
| Boonen [36] | 2013 | Netherlands | RCT | 90 | 90 | 62 | 56 | 69.0(8.0) | 65.0(8.8) | 44 months | Signature | MRI | OA |
| Chareancholvanich [37] | 2013 | Thailand | RCT | 40 | 40 | 85 | 90 | 69.5(55–84) | 70.3(53–85) | NR | Materialise | MRI | OA |
| Hamilton [38] | 2013 | USA | RCT | 26 | 26 | 46 | 73 | 68.1(52–86) | 67.6(51–88) | NR | TruMatch | CT | OA |
| Roh [39] | 2013 | Korea | RCT | 42 | 48 | 93 | 90 | 70.0(7.2) | 70.0(5.1) | NR | Signature | CT | OA |
| Ng [40] | 2014 | USA | pros | 51 | 27 | 67 | 52 | 65.6(7.5) | 79.3(8.1) | 3 months | Materialise | MRI | OA |
| Renson [41] | 2014 | Belgium | pros | 71 | 60 | 62 | 52 | 68.2(8.9) | 70.3(8.7) | 6 months | Materialise | MRI | OA |
| Dossett [42] | 2014 | USA | RCT | 44 | 44 | 7 | 14 | 66.0(7.7) | 66.0(8.6) | 24 months | Vanguard | MRI | arthritis |
| Abdel [43] | 2014 | France | RCT | 20 | 20 | 60 | 60 | 71.0(61–81) | 71(55–83) | 3 months | Materialise | MRI | arthritis |
| Chotanaphuti [44] | 2014 | Thailand | RCT | 40 | 40 | 88 | 88 | 69.7(5.5) | 69.3(5.5) | 1.5 months | TruMatch | CT | arthritis |
| Pfitzner [45] | 2014 | USA | RCT | 60 | 30 | 57 | 57 | 64.0(54–74) | 64.0(54–74) | 3 months | Visionaire | MRI | OA |
| Woolson [46] | 2014 | USA | RCT | 22 | 26 | 0 | 0 | NR | NR | 9 months | TruMatch | CT | no |
| Nabavi [47] | 2015 | Australia | retro | 82 | 84 | 52 | 52 | 64(44–85) | 65(45–88) | 12 months | MyKnee | CT | no |
| Thienpont [48] | 2015 | Belgium | retro | 75 | 75 | 67 | 67 | 65.6(9.6) | 67.8(11.0) | 1.5 months | Visionaire | NR | OA |
| Yan [49] | 2015 | China | RCT | 30 | 30 | 57 | 80 | 67.5(8.0) | 69.5(8.4) | 3 months | Materialise | MRI | OA* |
| Chen [50] | 2015 | Singapore | pros | 29 | 30 | 69 | 83 | 65.0(8.0) | 65.0(8.0) | 24 months | Materialise | MRI | OA |
| Kotela [51] | 2015 | Poland | RCT | 49 | 46 | 67 | 72 | 66.1(8.4) | 68.6(9.9) | 12 months | Signature | CT | OA |
| Rathod [52] | 2015 | USA | retro | 15 | 14 | 60 | 57 | 57.0(4.5) | 59.0(6.5) | 3 months | Visionaire | MRI | OA |
| Abane [53] | 2015 | France | RCT | 70 | 70 | 43 | 39 | 67.8(47–84) | 70.4(54–83) | 3 months | Visionaire | MRI | OA |
| Molicnik [54] | 2015 | Slovenia | RCT | 19 | 19 | 89 | 74 | 67.1(7.1) | 66.8(6.7) | NR | Materialise | MRI | OA |
| Ferrara [55] | 2015 | Italy | RCT | 15 | 15 | 60 | 53 | 75.3(6.7) | 74.5(7.2) | NR | Materialise | MRI | OA |
| Anderl [56] | 2016 | Austria | pros | 114 | 108 | 64 | 58 | 68.7(8.2) | 67.7(9.6) | 24 months | MyKnee | CT | OA |
| Boonen [57] | 2016 | Netherlands | RCT | 90 | 90 | 62 | 56 | 69.0(8.0) | 65.0(8.8) | 44 months | Signature | MRI | OA |
| Huijbregts [58] | 2016 | Australia | RCT | 69 | 64 | 58 | 50 | 66.7 (9.1) | 69.0(9.6) | 12 months | Visionaire | MRI | arthritis |
| Pourgiezis [59] | 2016 | Australia | pros | 45 | 45 | 80 | 56 | 69.5(1.5) | 69.3(1.5) | 3 months | Visionaire | MRI | OA |
| White [60] | 2016 | USA | pros | 21 | 42 | 67 | 67 | 59.1(7.4) | 59.8(6.7) | 24 months | iTotal | CT | OA |
| Culler [61] | 2017 | USA | retro | 126 | 122 | 62 | 64 | 69.7(8.4) | 68.3(9.5) | 3 months | NR | CT | arthritis |
| Kwon [62] | 2017 | Korea | retro | 48 | 50 | 96 | 94 | 73.0(4.3) | 72.0(6.5) | 3 months | Signature | MRI | OA |
| Zhu [63] | 2017 | Singapore | pros | 42 | 48 | 71 | 77 | 69.3(7.2) | 66.8(5.9) | 24 months | TruMatch | CT | OA |
| Vide [64] | 2017 | Portugal | RCT | 47 | 48 | 68 | 69 | 67.8(8.4) | 69.3(6.5) | NR | Visionaire | MRI | OA |
| Kosse [65] | 2018 | Netherlands | RCT | 21 | 21 | 62 | 43 | 62.7(4.5) | 63.4(4.2) | 12 months | Visionaire | MRI | OA |
| Steimle [66] | 2018 | USA | retro | 31 | 49 | NR | NR | 60.8(8.5) | 61.0(9.9) | NR | Materialise | MRI | OA |
| Tammachote [67] | 2018 | Thailand | RCT | 54 | 54 | 78 | 72 | 72.0(7.0) | 72.0(8.0) | 24 months | Visionaire | MRI | arthritis |
| Maus [68] | 2018 | Germany | RCT | 59 | 66 | 56 | 65 | 68.1(8.5) | 71.5(8.1) | 3 months | Imprint | MRI | OA |
| Stolarczyk [69] | 2018 | Poland | RCT | 30 | 30 | 73 | 60 | 70.2(5.9) | 69.6(7.1) | 3 months | Visionaire | MRI | OA |
| Leeuwen [70] | 2018 | Norway | RCT | 44 | 50 | 68 | 64 | 67.0(8.8) | 64.0(6.9) | 24 months | Signature | MRI | OA |
| NCT02539992 [71] | NR | Italy | RCT | 26 | 18 | 38 | 44 | NR | NR | 12 months | Triathlon | MRI | OA |
Date was expressed with mean (standard deviation). The underlined numbers represent minimum-maximum range. Abbreviations: PSI Patient-specific instrumentation, ST Standard TKA, NR Not reported, RCT Randomized controlled trial, pros Prospective non-RCT, retro Retrospective non-RCT, OA Osteoarthritis, USA The United States of America. Yan et al. (2015) recruited 93% OA and 6.7% RA